[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Huijie Zhang\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100658167","phase-2-jak1-inhibitor-ivarmacitinib-for-improving-pancreatic-islet-function-in-t1d-100658167",false,"NCT07845955","JAK1 Inhibitor Ivarmacitinib for Improving Pancreatic Islet Function in T1D","INhibiting JAK1 to Save Pancreatic Islet Function in Recently Established T1D(INSPIRE-T1D)","INSPIRE-T1D","Inclusion Criteria:\n\n1. Confirmed diagnosis of type 1 diabetes mellitus.\n2. Able to complete randomization and initiate treatment with the study drug within 100 days of being formally diagnosed with type 1 diabetes.\n3. Peak stimulated C-peptide level ≥ 0.2 pmol\u002FmL during the mixed-meal tolerance test performed in the screening period.\n4. Tested positive for at least one type 1 diabetes-associated autoantibody.\n\nExclusion Criteria:\n\n1. Presence of any autoimmune disease other than type 1 diabetes mellitus, except for stable autoimmune thyroid disease.\n2. Presence of active infection and\u002For fever.\n3. Known current or prior infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV), or serological evidence of such infection at screening.\n4. Active pulmonary tuberculosis, malignancy, etc.\n5. Severe hepatic impairment (AST or ALT \\>3 × upper limit of normal), or severe renal impairment or end-stage renal disease (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n6. Prior exposure to immunomodulatory agents, including baricitinib, ivarmacitinib, IL-1 receptor antagonists, tocilizumab (anti-IL-6 monoclonal antibody), infliximab (anti-TNF-α monoclonal antibody), interferons, etc.\n7. Severe cardiovascular disease such as angina pectoris, myocardial infarction, or stroke within the previous 6 months.\n8. Severe gastrointestinal disease.\n9. Surgical procedure performed within the past 6 months.\n10. Medical, psychological, or social conditions that, in the opinion of the investigator, may interfere with trial safety or proper completion.","ALL","10 Years","40 Years",{"count":21,"type":22},132,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a double-blind, randomized, placebo-parallel-controlled, multicenter study. The objective is to evaluate the efficacy and safety of Ivarmacitinib 8 mg administered for 52 weeks in preserving pancreatic β cell function in subjects with newly-onset type 1 diabetes mellitus. The study consists of a screening period (V1, up to 2 weeks), a 52-week double-blind treatment period (V2 to V14), and a 4-week safety follow-up period (V15).",[28],"T1DM - Type 1 Diabetes Mellitus",[30,31,32],"Type 1 Diabetes Mellitus","JAK1 Inhibitor","Ivarmacitinib","NOT_YET_RECRUITING","2026-09-27",{"date":36,"type":37},"2026-09-29","ACTUAL",{"date":39,"type":22},"2026-09-30",{"date":41,"type":22},"2029-12-31",{"name":43,"class":44},"Huijie Zhang","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100652732","phase-4-quartet-dkd-quadruple-therapy-for-type-2-diabetic-nephropathy-100652732","NCT07775846","QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic Nephropathy","QUAdruple Therapy With RASi, Empagliflozin, Finerenone, and Mazdutide in Type 2 Diabetes and Early Treatment of Nephropathy(QUARTET-DKD)","Inclusion Criteria:\n\n* Age ≥18 years, with a confirmed diagnosis of type 2 diabetes mellitus (T2DM).\n* Receiving a standard dose of an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) therapy for at least 4 consecutive weeks prior to screening, with the dose expected to remain stable throughout the study period.\n* Body Mass Index (BMI) ≥ 24.0 kg\u002Fm2.\n* Mean urine albumin-to-creatinine ratio (UACR) ≥ 100 mg\u002Fg and \\\u003C 5000 mg\u002Fg, calculated from first morning void urine samples collected over 3 consecutive days.\n* Estimated glomerular filtration rate (eGFR) based on the CKD-EPI formula ≥ 30 mL\u002Fmin\u002F1.73m2 and ≤ 90 mL\u002Fmin\u002F1.73m2.\n* Serum potassium level ≤ 4.8 mmol\u002FL.\n* Glycated hemoglobin (HbA1c) \\\u003C 11%.\n* Voluntarily understood and signed the written Informed Consent Form (ICF).\n\nExclusion Criteria:\n\n* Definite diagnosis of non-diabetic kidney disease (e.g., IgA nephropathy, polycystic kidney disease, lupus nephritis, etc).\n* Personal or family history of medullary thyroid carcinoma (MTC), or a diagnosis of multiple endocrine neoplasia syndrome type 2 (MEN 2).\n* History of severe acute or chronic pancreatitis.\n* History of diabetic ketoacidosis (DKA).\n* Symptomatic hypotension during the screening period, or a resting systolic blood pressure (SBP) \\\u003C 110 mmHg.\n* Refractory hypertension, defined as a resting SBP \\> 170 mmHg despite the concurrent use of three antihypertensive medications.\n* History of severe dehydration, severe diarrhea, or acute volume depletion within 30 days prior to screening.\n* History of acute kidney injury (AKI) within 30 days prior to screening.\n* Use of traditional Chinese medicines with potential proteinuria-lowering effects (e.g., Keluoxin capsules, Huangkui capsules, or Shenyan Kangfu tablets) within 30 days prior to screening.\n* Use of potassium-sparing diuretics (e.g., triamterene or amiloride) or mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone, or finerenone) within 2 months prior to screening.\n* Use of GLP-1 receptor agonists, GLP-1\u002FGIP dual receptor agonists, or GLP-1\u002Fglucagon (GCG) dual receptor agonists within 6 months prior to screening.\n* Current use of strong CYP3A4 inhibitors (e.g., itraconazole or clarithromycin) or CYP3A4 inducers that may significantly interfere with finerenone metabolism.\n* Myocardial infarction, unstable angina, stroke, or hospitalization due to heart failure (NYHA Class III-IV) within 3 months prior to screening.\n* Active urogenital tract infection, or a history of urogenital tract infection associated with the prior use of SGLT2 inhibitors.\n* Women who are pregnant, planning to become pregnant, or lactating.\n* Inability to complete the 6-month follow-up due to general health conditions or geographic relocation.\n* Any other condition that, in the opinion of the investigator, renders the participant unsuitable for participation in the study.","18 Years","70 Years",{"count":56,"type":22},820,[58],"PHASE4","This study employs a prospective, randomized, double-blind, parallel-controlled design, aiming to enroll adult participants with type 2 diabetic kidney disease (DKD) who meet the eligibility criteria. With an angiotensin receptor blocker (ARB) as the background therapy, all participants will be randomized in a 1:1:1:1 ratio into four treatment groups:\n\nGroup 1 (G1): ARB + empagliflozin + finerenone placebo + mazdutide placebo; Group 2 (G2): ARB + empagliflozin + finerenone + mazdutide placebo; Group 3 (G3): ARB + empagliflozin + mazdutide + finerenone placebo; Group 4 (G4): ARB + empagliflozin + mazdutide + finerenone. The primary comparisons include G2 vs. G1, G3 vs. G1, G4 vs. G2, and G4 vs. G3, designed to evaluate the superiority of triple therapy over dual therapy, and quadruple therapy over triple therapy, in reducing the urine albumin-to-creatinine ratio (UACR).",[61],"Type 2 Diabetic Kidney Disease",[63,64,65,66,67,68],"SGLT2 inhibitors","Mineralocorticoid receptor antagonists","GLP-1 receptor agonists","Randomized controlled trial","angiotensin II receptor blocker","urinary albumin-to-creatinine ratio","2026-08-16",{"date":71,"type":37},"2026-08-20",{"date":73,"type":22},"2026-09-01",{"date":75,"type":22},"2029-06-30",{"name":43,"class":44},""]